Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis
Ulcerative Colitis, Ulcerative Colitis Exacerbation, Protozoan Infections
About this trial
This is an interventional treatment trial for Ulcerative Colitis focused on measuring ulcerative colitis, helminths, intestinal protozoan, nitazoxanide
Eligibility Criteria
Inclusion Criteria:
- Patients with ulcerative colitis before therapy and surgery
- Residents of Tashkent region which does not have any complaints from the gastrointestinal tract (control group)
Exclusion Criteria:
- Patients with a diagnosis of Crohn's disease
- Patients with a toxic megacolon,
- Patients with a abdominal abscess, -
- Patients with a symptomatic colonic stricture,
- Patients with a stoma,
- Patients with a a history of colectomy,
- An increased risk of infectious complications (e.g. as a result of recent pyogenic infection, enteric pathogens detected on stool analysis, active or latent tuberculosis, immunodeficiency, hepatitis B or C, or recent live vaccination),
- Clinically meaningful laboratory abnormalities,
- Pregnancy or lactation,
- An unstable or uncontrolled medical disorder,
- An anticipated requirement for major surgery,
- Colonic dysplasia or adenomas,
- Malignant neoplasms.
- Patients which operated,
- Ever used immunosuppressants or biological drugs
- In the presence of pathologic bacteria in gut microbiota, including Clostridium difficile, Salmonella spp, Shigella spp, Campylobacter spp, Yersinia spp, and Mycobacteria.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Active Comparator
No Intervention
Active Comparator
Placebo Comparator
Active Comparator
Patients with ulcerative colitis
Participants (control group)
UC patients (cohort 1)
UC patients (cohort 2)
UC patients (cohort 3)
Patients with ulcerative colitis in this group will take nitazoxanide per os
only parasitological diagnostics will be performed in this group to compare the prevalence of some representatives of the microbiota
Patients with ulcerative colitis in this group will take standart therapy (mesalazin)
Patients with ulcerative colitis in this group will take placebo tabletes
Patients with ulcerative colitis in this group will take combination standart therapy with nitazoxanide